The Role of Antiangiogenic Drugs in the Treatment of Diabetic Macular Edema

Simple item page
dc.creatoro’g’li, Naimov Dilshod Qayim
dc.date2023-12-29
dc.date.accessioned2024-10-12T12:35:52Z
dc.date.available2024-10-12T12:35:52Z
dc.descriptionThe article presents the characteristics of the first antiangiogenic drug registered for the treatment of diabetic macular edema, ranibizumab, as well as the new long-acting drug brolucizumab.en-US
dc.formatapplication/pdf
dc.identifierhttps://journals.proindex.uz/index.php/JSML/article/view/422
dc.identifier.urihttps://dspace.umsida.ac.id/handle/123456789/37453
dc.languageeng
dc.publisherPro Indexen-US
dc.relationhttps://journals.proindex.uz/index.php/JSML/article/view/422/361
dc.sourceJournal of Science in Medicine and Life; Vol. 1 No. 4 (2023): Journal of Science in Medicine and Life; 97-101en-US
dc.source2992-9202
dc.subjectdiabetic macular edemaen-US
dc.subjectantiangiogenic therapyen-US
dc.subjectranibizumaben-US
dc.titleThe Role of Antiangiogenic Drugs in the Treatment of Diabetic Macular Edemaen-US
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.typePeer-reviewed Articleen-US
Files
Collections
Journal of Science in Medicine and Life